News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
527,083 Results
Type
Article (38781)
Company Profile (74)
Press Release (488228)
Section
Business (151115)
Career Advice (2394)
Deals (27604)
Drug Delivery (77)
Drug Development (72366)
Employer Resources (140)
FDA (13420)
Job Trends (12134)
News (269474)
Policy (26814)
Tag
Academia (2509)
Africa (713)
Alliances (37901)
Alzheimer's disease (1160)
Antibody-drug conjugate (ADC) (53)
Approvals (13341)
Arizona (97)
Artificial intelligence (62)
Asia (32625)
Australia (6815)
Bankruptcy (299)
Best Places to Work (9673)
Biotechnology (61)
Breast cancer (52)
C2C Services and Suppliers (53242)
California (1550)
Canada (837)
Cancer (477)
Career advice (2007)
Cell therapy (113)
China (128)
Clinical research (56758)
Collaboration (118)
Colorado (63)
Connecticut (59)
COVID-19 (2365)
Cystic fibrosis (62)
Data (299)
Diabetes (75)
Diagnostics (5340)
Drug pricing (60)
Earnings (52275)
Employer resources (125)
Europe (72541)
Events (71196)
Executive appointments (155)
FDA (13627)
Florida (234)
Funding (130)
Gene therapy (89)
GLP-1 (498)
Government (4002)
Healthcare (15867)
Hotbed/Location (349628)
Illinois (206)
Indiana (135)
Infectious disease (2393)
Inflammatory bowel disease (85)
Interviews (514)
IPO (12267)
Job creations (2568)
Job search strategy (1659)
Kansas (79)
Layoffs (356)
Legal (5656)
Liver cancer (54)
Lung cancer (116)
Manufacturing (74)
Maryland (346)
Massachusetts (1095)
Medical device (10319)
Medtech (10323)
Mergers & acquisitions (15219)
Metabolic disorders (237)
Michigan (111)
Minnesota (159)
Neuroscience (1316)
New Jersey (474)
New York (510)
NextGen Class of 2024 (5502)
Non-profit (3954)
North Carolina (484)
Northern California (704)
Obesity (137)
Ohio (85)
Opinion (173)
Patents (73)
Pennsylvania (448)
People (49402)
Phase I (17351)
Phase II (24962)
Phase III (19134)
Pipeline (109)
Postmarket research (2296)
Preclinical (7071)
Press Release (54)
Rare diseases (120)
Real estate (4070)
Recruiting (55)
Regulatory (18035)
Research institute (2097)
Resumes & cover letters (352)
South America (977)
Southern California (666)
Startups (2712)
Texas (196)
United States (6866)
Vaccines (430)
Washington State (210)
Weight loss (125)
Date
Today (102)
Last 7 days (565)
Last 30 days (2051)
Last 365 days (32167)
2024 (22705)
2023 (34093)
2022 (44521)
2021 (47767)
2020 (46284)
2019 (39627)
2018 (30032)
2017 (26943)
2016 (25614)
2015 (29990)
2014 (22447)
2013 (18240)
2012 (19474)
2011 (20496)
2010 (18093)
527,083 Results for "inspyr formerly known as genspera".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
FDA
Association for Diagnostics & Laboratory Medicine (formerly AACC) survey finds that FDA’s final laboratory developed tests rule will hinder patient care for underserved communities
September 5, 2024
·
4 min read
Business
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.
April 15, 2024
·
3 min read
Biotech Beach
Allez Health Announces $60 Million Capital Raise
Allez Health Inc., formerly known as Zense-Life Inc., an emerging biosensor venture founded by proven experts in the continuous glucose monitoring space, announced a $60 million Series A+ financing.
May 22, 2024
·
2 min read
FDA
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.
March 8, 2024
·
14 min read
Biotech Bay
Lykos Therapeutics (Formerly MAPS PBC) Announces Publication Examining the Effects of MDMA-Assisted Therapy on Emotional Coping Skills and Self-Experience in PTSD
Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”) announced that PLOS ONE has published the first comparison of the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe post-traumatic stress disorder (“PTSD”).
January 10, 2024
·
9 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
1 of 52,709
Next